Neovasc Inc. Reports Second Quarter 2009 Financi...(1585066 1666616 ----------------...),Health

Date:8/19/2009

1,585,066 1,666,616 ------------------------------------------------------------------------- SHAREHOLDERS' EQUITY Share capital 60,588,307 58,607,066 Contributed surplus 4,563,255 4,436,804 Deficit (62,966,654) (59,889,963) ------------------------------------------------------------------------- 2,184,908 3,153,907 ------------------------------------------------------------------------- $ 3,769,974 $ 4,820,523 ------------------------------------------------------------------------- ------------------------------------------------------------------------- Neovasc Inc. (formerly Medical Ventures Corp.) Consolidated Statements of Operations, Comprehensive Loss and Deficit For the three and six months ended June 30 ------------------------------------------------------------------------- ------------------------------------------------------------------------- Three months ended June 30 Six months ended June 30 2009 2008 2009 2008 ------------------------------------------------------------------------- SALES Product sales $ 529,769 $ 433,061 $ 828,399 $ 837,924 Consulting services 70,555 - 127,409 28,622 ------------------------------------------------------------------------- 600,324 433,061 955,808 866,546 COST OF SALES, including underutilized capacity of $16,038 (2008: $25,144) 277,265 220,344 427,025 428,604 --------------------------------------------------
'/>"/>

SOURCE Neovasc Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine news :

1. Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options
2. Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results
3. Neovasc Announces Agreement With LeMaitre Vascular for Exclusive Distribution Rights to its Biological Vascular Strips
4. Neovasc Receives CE Mark Approval for Peripatch(TM) Aegis Staple Line Reinforcement Product
5. Neovasc to Raise $2 Million in Non-Brokered Private Placement
6. Neovasc Inc. Reports Year 2008 Financial Results
7. Neovasc Completes $2 Million Non-Brokered Private Placement
8. Positive Results for Ophthotechs Novel Therapy for Wet AMD - Study of Anti-PDGF and Anti-VEGF Therapy Shows Significant Neovascular Regression and Enhanced Visual Outcome
9. Neovasc Inc. Reports First Quarter 2009 Financial Results
10. Neovasc Inc. Postpones Plans for U.S. Listing to Focus Funds on Commercializing Its Reducer Device for Refractory Angina
11. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites